Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
Van Zyl-Smit RN, Kerstjens HA, Maspero JF, Kostikas K, Hosoe M, Tanase AM, D'Andrea P, Mezzi K, Brittain D, Lawrence D, Chapman KR. Van Zyl-Smit RN, et al. Among authors: kerstjens ha. Respir Med. 2023 May;211:107172. doi: 10.1016/j.rmed.2023.107172. Epub 2023 Mar 9. Respir Med. 2023. PMID: 36906187 Free article.
Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.
Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, Engel M, Bour L, Verkleij CB, Moroni-Zentgraf P, Bateman ED. Kerstjens HA, et al. Lancet Respir Med. 2015 May;3(5):367-76. doi: 10.1016/S2213-2600(15)00031-4. Epub 2015 Feb 12. Lancet Respir Med. 2015. PMID: 25682232 Clinical Trial.
Adrenomedullin optimises mortality prediction in COPD patients.
Brusse-Keizer M, Zuur-Telgen M, van der Palen J, VanderValk P, Kerstjens H, Boersma W, Blasi F, Kostikas K, Milenkovic B, Tamm M, Stolz D. Brusse-Keizer M, et al. Respir Med. 2015 Jun;109(6):734-42. doi: 10.1016/j.rmed.2015.02.013. Epub 2015 Mar 6. Respir Med. 2015. PMID: 25937049 Free article.
Indacaterol vs tiotropium in COPD patients classified as GOLD A and B.
Mahler DA, Kerstjens HA, Donohue JF, Buhl R, Lawrence D, Altman P. Mahler DA, et al. Among authors: kerstjens ha. Respir Med. 2015 Aug;109(8):1031-9. doi: 10.1016/j.rmed.2015.05.012. Epub 2015 May 22. Respir Med. 2015. PMID: 26094050 Free article. Clinical Trial.
Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status.
Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M, Schmidt H, Engel M, Bateman ED. Kerstjens HA, et al. Respir Med. 2016 Aug;117:198-206. doi: 10.1016/j.rmed.2016.06.013. Epub 2016 Jun 14. Respir Med. 2016. PMID: 27492532 Free article. Clinical Trial.
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P; IRIDIUM trial investigators. Kerstjens HAM, et al. Lancet Respir Med. 2020 Oct;8(10):1000-1012. doi: 10.1016/S2213-2600(20)30190-9. Epub 2020 Jul 9. Lancet Respir Med. 2020. PMID: 32653074 Clinical Trial.
Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
van Geffen WH, Carpaij OA, Westbroek LF, Seigers D, Niemeijer A, Vonk JM, Kerstjens HAM. van Geffen WH, et al. Respir Med. 2020 Sep;171:106064. doi: 10.1016/j.rmed.2020.106064. Epub 2020 Jul 3. Respir Med. 2020. PMID: 32917359 Free article. Clinical Trial.
362 results